Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $152,075.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 5,500 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $27.65, for a total transaction of $152,075.00. Following the sale, the insider now directly owns 75,294 shares in the company, valued at $2,081,879.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.52, for a total transaction of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $143,052.00.

Akero Therapeutics Trading Down 0.2 %

Akero Therapeutics stock opened at $28.00 on Thursday. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $51.24. The firm’s 50-day moving average is $26.36 and its 200-day moving average is $23.83. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The company has a market cap of $1.94 billion, a P/E ratio of -8.75 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of analyst reports. Wolfe Research assumed coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AKRO. Russell Investments Group Ltd. boosted its holdings in shares of Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares during the period. Quarry LP increased its holdings in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares during the period. Quest Partners LLC acquired a new position in Akero Therapeutics during the 4th quarter valued at about $75,000. Headlands Technologies LLC boosted its stake in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after purchasing an additional 1,030 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.